re: Ann: LANI Phase III clinical trials in As... yes - compared to japan......
Shikibo, Maskmakers Gain After Japan Confirms First Flu Death
Share | Email | Print | A A A
By Norie Kuboyama
Aug. 17 (Bloomberg) -- Shikibo Ltd., Daiwabo Holdings Co. and other makers of materials used in medical masks gained in Tokyo trading after Japan confirmed its first death from swine flu.
Osaka-based Shikibo surged 11 percent to 203 yen as of 9:38 a.m. on the Tokyo Stock Exchange, set for the highest close since April 30. It was the biggest gainer on the Topix index, which fell as much as 1.6 percent.
A man, aged in his 50s on the southern island of Okinawa, died on Aug. 15 after contracting the virus, according to a statement from the Okinawa swine flu task force.
Daiwabo climbed as much as 9 percent to 424 yen. Fujibo Holdings Inc. soared up to 11 percent to 166 yen, while Unitika Ltd. gained as much as 5.6 percent to 94 yen.
Eiken Chemical Co., a clinical reagent maker, jumped as much as 8.4 percent to 1,045 yen. Daiichi Sankyo Co., which is developing a flu drug, gained as much as 3.5 percent.
Chugai Pharmaceutical Co., the Japanese seller of the influenza drug Tamiflu, increased up to 2.1 percent.
To contact the reporter on this story: Norie Kuboyama in Tokyo at [email protected].
- Forums
- ASX - By Stock
- BTA
- Ann: LANI Phase III clinical trials in Asia prove
Ann: LANI Phase III clinical trials in Asia prove, page-20
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online